Nidhi Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nidhi Singh has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Avijit Mazumder
Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, 201306 Uttar Pradesh, India
2 shared publications - Priyanka Bansal
Noida Institute of Engineering and Technology (Pharmacy Institute), Knowledge Park-II, Greater Noida, Uttar Pradesh, 201306, India
2 shared publications
Latest Publications
- 28 August 2026
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 21, 1-13
Molecular Insights into Signalling Pathways and Therapeutic Monitoring of Chronic Low-grade Inflammation-associated Obesity
Introduction: Obesity has emerged as a major global public health concern. It is a multifactorial condition encompassing genetic, environmental, socioeconomic, and psychosocial factors. This narrative review aims to highlight the key pathophysiological processes associated with chronic low-grade inflammation (CLGI) in obesity. Methods: Data collection was performed using the PubMed, Scopus, Web of Science, and Google Scholar databases, using the search terms “chronic low-grade inflammation”, “pathophysiology of obesity,” and “metabolic syndrome” to obtain relevant articles. Results: The pathophysiological sequence underlying CLGI-associated obesity begins with adipose tissue expansion, during which hypertrophic adipocytes trigger cellular stress manifested as hypoxia and ER stress, accompanied by the release of damage-associated molecular patterns (DAMPs). This initiates a vicious cycle involving the recruitment of macrophages and their proinflammatory M1 polarization, with activation of inflammatory pathways, such as NF-κB and the NLRP3 inflammasome. These changes further contribute to the induction of systemic insulin resistance and metabolic dysregulation. Discussion: Both tissue and systemic biomarkers are valuable in identifying and monitoring CLGI-associated obesity. Treatment approaches ranging from pharmacological agents and bariatric surgery to dietary modifications, exercise, and microbiome-based therapies are relevant for managing inflammation and metabolic health. Conclusion: In conclusion, strategic immunotargeting of CLGI through context-specific interventions can serve as an innovative therapeutic strategy to treat CLGI-associated obesity and potentially mitigate the resulting comorbid metabolic burden. Future efforts should prioritize the development of multi-marker approaches within precision medicine frameworks to enable more individualized care for patients with CLGI-associated obesity.
- 28 August 2026
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 21, 1-13
Molecular Insights into Signalling Pathways and Therapeutic Monitoring of Chronic Low-grade Inflammation-associated Obesity
Introduction: Obesity has emerged as a major global public health concern. It is a multifactorial condition encompassing genetic, environmental, socioeconomic, and psychosocial factors. This narrative review aims to highlight the key pathophysiological processes associated with chronic low-grade inflammation (CLGI) in obesity. Methods: Data collection was performed using the PubMed, Scopus, Web of Science, and Google Scholar databases, using the search terms “chronic low-grade inflammation”, “pathophysiology of obesity,” and “metabolic syndrome” to obtain relevant articles. Results: The pathophysiological sequence underlying CLGI-associated obesity begins with adipose tissue expansion, during which hypertrophic adipocytes trigger cellular stress manifested as hypoxia and ER stress, accompanied by the release of damage-associated molecular patterns (DAMPs). This initiates a vicious cycle involving the recruitment of macrophages and their proinflammatory M1 polarization, with activation of inflammatory pathways, such as NF-κB and the NLRP3 inflammasome. These changes further contribute to the induction of systemic insulin resistance and metabolic dysregulation. Discussion: Both tissue and systemic biomarkers are valuable in identifying and monitoring CLGI-associated obesity. Treatment approaches ranging from pharmacological agents and bariatric surgery to dietary modifications, exercise, and microbiome-based therapies are relevant for managing inflammation and metabolic health. Conclusion: In conclusion, strategic immunotargeting of CLGI through context-specific interventions can serve as an innovative therapeutic strategy to treat CLGI-associated obesity and potentially mitigate the resulting comorbid metabolic burden. Future efforts should prioritize the development of multi-marker approaches within precision medicine frameworks to enable more individualized care for patients with CLGI-associated obesity.
- Open Access
- 30 May 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1197-1210
A Review on Potential Footprints of Piper methysticum for Chronic Disease Management
Background: For centuries, Kava (Piper methysticum) has been incorporated as medicine in the Pacific Islands, and modern studies now confirm its therapeutic value on several chronic diseases. Aim: This review aims to explore the modes of action of kavalactones and flavokavains in kava to treat neurological disorders, cancer and inflammation. Methods: A systematic review was conducted through PubMed, Scopus, Science Direct and Google Scholar databases on articles between 2010 and 2025 by investigating keywords that matched both kava and chronic diseases. Results: Kavalactones, including kavain and methysticin, control excessive neuron activity by interacting with GABA receptors and preventing sodium channel activity, which supports kava’s historical application for anxiety treatment and its new use in treating epilepsy and providing neuroprotection. Flavokavain A shows strong anti-inflammatory properties because it prevents NF-κB pathway destruction while it activates the protective Nrf2 antioxidant system. Flavokavains induce cancer cell death through various mechanisms, including disrupting the equilibrium between pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins and blocking the blood flow needed by tumours. The therapeutic potential of flavokavain B, which exists in organic solvent extracts, creates a serious risk because it causes damage to the liver. Conclusion: kava’s kavalactones and flavokavains offer compelling therapeutic benefits for neurological disorders, cancer, and inflammation — calming neural excitability, inducing cancer cell death, and activating antioxidant defences. Moving forward, rigorous clinical studies are needed to fully unlock this ancient botanical’s modern medicinal benefits. Major Findings: Kava’s bioactive components kavalactones and flavokavains show remarkable therapeutic potential like neuroprotection, anxiolysis, and anti-inflammatory effects through GABAergic and NF-κB/Nrf2 pathways, while demonstrating potent anticancer activity via apoptosis and angiogenesis inhibition.
- 30 May 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1197-1210
Open AccessA Review on Potential Footprints of Piper methysticum for Chronic Disease Management
Background: For centuries, Kava (Piper methysticum) has been incorporated as medicine in the Pacific Islands, and modern studies now confirm its therapeutic value on several chronic diseases. Aim: This review aims to explore the modes of action of kavalactones and flavokavains in kava to treat neurological disorders, cancer and inflammation. Methods: A systematic review was conducted through PubMed, Scopus, Science Direct and Google Scholar databases on articles between 2010 and 2025 by investigating keywords that matched both kava and chronic diseases. Results: Kavalactones, including kavain and methysticin, control excessive neuron activity by interacting with GABA receptors and preventing sodium channel activity, which supports kava’s historical application for anxiety treatment and its new use in treating epilepsy and providing neuroprotection. Flavokavain A shows strong anti-inflammatory properties because it prevents NF-κB pathway destruction while it activates the protective Nrf2 antioxidant system. Flavokavains induce cancer cell death through various mechanisms, including disrupting the equilibrium between pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins and blocking the blood flow needed by tumours. The therapeutic potential of flavokavain B, which exists in organic solvent extracts, creates a serious risk because it causes damage to the liver. Conclusion: kava’s kavalactones and flavokavains offer compelling therapeutic benefits for neurological disorders, cancer, and inflammation — calming neural excitability, inducing cancer cell death, and activating antioxidant defences. Moving forward, rigorous clinical studies are needed to fully unlock this ancient botanical’s modern medicinal benefits. Major Findings: Kava’s bioactive components kavalactones and flavokavains show remarkable therapeutic potential like neuroprotection, anxiolysis, and anti-inflammatory effects through GABAergic and NF-κB/Nrf2 pathways, while demonstrating potent anticancer activity via apoptosis and angiogenesis inhibition.